Joyce Tsai

2.3k total citations · 1 hit paper
31 papers, 873 citations indexed

About

Joyce Tsai is a scholar working on Psychiatry and Mental health, Pharmacology and Clinical Psychology. According to data from OpenAlex, Joyce Tsai has authored 31 papers receiving a total of 873 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Psychiatry and Mental health, 8 papers in Pharmacology and 8 papers in Clinical Psychology. Recurrent topics in Joyce Tsai's work include Bipolar Disorder and Treatment (13 papers), Treatment of Major Depression (6 papers) and Schizophrenia research and treatment (6 papers). Joyce Tsai is often cited by papers focused on Bipolar Disorder and Treatment (13 papers), Treatment of Major Depression (6 papers) and Schizophrenia research and treatment (6 papers). Joyce Tsai collaborates with scholars based in United States, Japan and India. Joyce Tsai's co-authors include Michael G. Douglas, Gerald M. Reaven, Jian Luo, Cynthia S. Sullivan, Antony Loebel, Richard Hector, Yongcai Mao, Kenneth S. Koblan, Josephine Cucchiaro and Jeanne Cheung and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Pharmacology and Experimental Therapeutics and Neuropsychopharmacology.

In The Last Decade

Joyce Tsai

30 papers receiving 846 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication

2023 96 citations Guy M. Goodwin, David Feifel et al. Neuropsychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joyce Tsai United States	14	318	175	149	109	106	31	873
Xiaofeng Guo China	24	418 1.3×	315 1.8×	53 0.4×	127 1.2×	74 0.7×	54	1.5k
Mats Lindström Sweden	13	157 0.5×	111 0.6×	136 0.9×	40 0.4×	103 1.0×	17	628
Ladan Kashani Iran	19	273 0.9×	242 1.4×	62 0.4×	203 1.9×	186 1.8×	61	1.4k
S Steinberg United States	6	640 2.0×	325 1.9×	128 0.9×	108 1.0×	129 1.2×	10	1.5k
Maria Elisabetta Raggi Italy	19	231 0.7×	197 1.1×	95 0.6×	17 0.2×	123 1.2×	32	1.0k
Joseph Tai Canada	18	433 1.4×	120 0.7×	38 0.3×	183 1.7×	146 1.4×	51	1.4k
María Campos Spain	20	344 1.1×	535 3.1×	213 1.4×	31 0.3×	82 0.8×	27	1.4k
E. J. M. Pennings Netherlands	18	372 1.2×	225 1.3×	213 1.4×	22 0.2×	275 2.6×	41	1.3k
Siamak Afshin‐Majd Iran	15	217 0.7×	41 0.2×	42 0.3×	49 0.4×	138 1.3×	33	744
David M. Ball United Kingdom	13	382 1.2×	148 0.8×	36 0.2×	37 0.3×	119 1.1×	23	1.1k

Countries citing papers authored by Joyce Tsai

Since Specialization

Citations

This map shows the geographic impact of Joyce Tsai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joyce Tsai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joyce Tsai more than expected).

Fields of papers citing papers by Joyce Tsai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joyce Tsai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joyce Tsai. The network helps show where Joyce Tsai may publish in the future.

Co-authorship network of co-authors of Joyce Tsai

This figure shows the co-authorship network connecting the top 25 collaborators of Joyce Tsai. A scholar is included among the top collaborators of Joyce Tsai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joyce Tsai. Joyce Tsai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goodwin, Guy M., Anna Nowakowska, Boadie W. Dunlop, et al.. (2025). Results From a Long-Term Observational Follow-Up Study of a Single Dose of Psilocybin for a Treatment-Resistant Episode of Major Depressive Disorder. The Journal of Clinical Psychiatry. 86(1). 3 indexed citations

Marwood, Lindsey, et al.. (2024). The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression. Journal of Psychiatric Research. 180. 198–203. 3 indexed citations

Goodwin, Guy M., David Feifel, John R. Kelly, et al.. (2023). Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication. Neuropsychopharmacology. 48(10). 1492–1499. 96 indexed citations breakdown →

Iyo, Masaomi, Jun Ishigooka, Masatoshi Nakamura, et al.. (2021). Safety and Effectiveness of Lurasidone in Patients with Schizophrenia: A 12-Week, Open-Label Extension Study. Neuropsychiatric Disease and Treatment. Volume 17. 2683–2695. 9 indexed citations

Loebel, Antony, Kenneth S. Koblan, Joyce Tsai, et al.. (2021). A Randomized, Double-blind, Placebo-controlled Proof-of-Concept Trial to Evaluate the Efficacy and Safety of Non-racemic Amisulpride (SEP-4199) for the Treatment of Bipolar I Depression. Journal of Affective Disorders. 296. 549–558. 19 indexed citations

Miller, Brian J., Cynthia Siu, Michael Tocco, et al.. (2020). Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. Comprehensive Psychiatry. 102. 152195–152195. 5 indexed citations

Grilo, Carlos M., Susan L. McElroy, James I. Hudson, et al.. (2020). Efficacy and safety of dasotraline in adults with binge-eating disorder: a randomized, placebo-controlled, fixed-dose clinical trial. CNS Spectrums. 26(5). 481–490. 20 indexed citations

Goldberg, Joseph F., Cynthia Siu, Yongcai Mao, et al.. (2020). Major depressive disorder with mixed features and treatment response to lurasidone: A symptom network model. Journal of Affective Disorders. 277. 1045–1054. 12 indexed citations

Rabinowitz, Jonathan, Nina R. Schooler, Mads K. Dalsgaard, et al.. (2019). Consistency checks to improve measurement with the Montgomery-Asberg Depression Rating Scale (MADRS). Journal of Affective Disorders. 256. 143–147. 11 indexed citations

10.

Wigal, Sharon B., Seth C. Hopkins, Kenneth S. Koblan, et al.. (2019). Efficacy and Safety of Dasotraline in Children With ADHD: A Laboratory Classroom Study. Journal of Attention Disorders. 24(2). 192–204. 19 indexed citations

11.

Clayton, Anita H., et al.. (2018). Effect of Lurasidone on Sexual Function in Major Depressive Disorder Patients With Subthreshold Hypomanic Symptoms (Mixed Features). The Journal of Clinical Psychiatry. 79(5). 9 indexed citations

12.

Raison, Charles L., et al.. (2018). C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behavior and Immunity. 73. 717–724. 27 indexed citations

13.

Swann, Alan C., et al.. (2017). Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis. CNS Spectrums. 22(2). 228–235. 11 indexed citations

14.

Forester, Brent P., et al.. (2017). Safety and Effectiveness of Long-Term Treatment with Lurasidone in Older Adults with Bipolar Depression: Post-Hoc Analysis of a 6-Month, Open-Label Study. American Journal of Geriatric Psychiatry. 26(2). 150–159. 10 indexed citations

15.

Tsai, Joyce, et al.. (2017). Lurasidone for major depressive disorder with mixed features and anxiety: a post-hoc analysis of a randomized, placebo-controlled study. CNS Spectrums. 22(2). 236–245. 16 indexed citations

16.

Sajatovic, Martha, Brent P. Forester, Joyce Tsai, et al.. (2016). Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression. The Journal of Clinical Psychiatry. 77(10). e1324–e1331. 26 indexed citations

17.

Forester, Brent P., Martha Sajatovic, Joyce Tsai, et al.. (2015). Efficacy and Safety of Long-term Treatment with Lurasidone in Older Adults with Bipolar Depression: Results of a 6 Month Open-label Study. American Journal of Geriatric Psychiatry. 23(3). S170–S171. 1 indexed citations

18.

Bose, Anjana, et al.. (2012). Early Non-Response in Patients with Severe Depression. Clinical Drug Investigation. 32(6). 373–385. 18 indexed citations

19.

Luo, Jian, Jeanne Cheung, Jocalyn Clark, et al.. (1999). Novel Terpenoid-Type Quinones Isolated from Pycnanthus angolensis of Potential Utility in the Treatment of Type 2 Diabetes. Journal of Pharmacology and Experimental Therapeutics. 288(2). 529–534. 34 indexed citations

20.

Luo, Jian, Jeanne Cheung, Joyce Tsai, et al.. (1998). Masoprocol (nordihydroguaiaretic acid): a new antihyperglycemic agent isolated from the creosote bush (Larrea tridentata). European Journal of Pharmacology. 346(1). 77–79. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact